Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of PF-07985631 in Healthy Adult Participants
NCT06994897Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07985631 in IgA nephropathy (IgAN) (13 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE), Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria and 2 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
PF-07985631
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06994897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994897.